Ascendis Pharma (ASND)
3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025
3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025
📈 **POSITIVE** • Medium confidence analysis (68%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business